NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Power Queen, a global LiFePO4 battery brand, today announced the launch of its latest high-performance lithium battery line, just ahead of Black Friday 2025. Designed for RV owners, boaters, and home-backup enthusiasts, the new batteries combine long lifespan, fast charging, and sustainable energy benefits, providing a practical alternative to both cheap lead-acid options and premium competitors. "How big is the discount today?" to "What actually gives me reliable ...

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Montauk Metals Inc. (TSX-V: MTK) (the “Company” or “Montauk”) filed a corporate assignment into bankruptcy pursuant to the Bankruptcy and Insolvency Act (Canada) (the “BIA”). The filing comes after the Board was unable to reach a settlement with its creditors. The Fuller Landau Group Inc. has been appointed as the Licensed Insolvency Trustee (the “Trustee”) under th ...

Core Insights - AlphaTON Capital has not engaged in equity line financing with ATW Partners and maintains a low debt to equity ratio of 7% [1][11] - The company has transformed its balance sheet into a diversified portfolio of digital assets since its PIPE funding on September 25, 2025, focusing on the Telegram ecosystem [2][3] - AlphaTON Capital aims to create a closed-loop ecosystem that integrates various digital assets and applications, enhancing value across its operations [4][11] Strategic Initiatives - The company has launched the "AlphaTON World Tour" to educate institutional investors about the intersection of social media and decentralized finance [7] - AlphaTON is transitioning to an active operator model, incubating and acquiring cash-flowing businesses within the Telegram Mini-App economy [7] - The company is leveraging its legacy biotech assets while exploring innovations at the intersection of healthcare and blockchain technology [11] Financial Overview - AlphaTON has completed an acquisition of approximately $30 million in digital assets, with a current total asset value of $28.6 million [8] - The company has deployed 4 million TON into institutional staking contracts, generating predictable network rewards [11] - AlphaTON's treasury is currently trading at a 0.70 mNAV, indicating it is undervalued [8] Strategic Partnerships and Acquisitions - AlphaTON has executed a binding LOI with Animoca Brands to acquire a 51% equity interest in GAMEE, a mobile gaming platform [11] - The company has entered a joint venture with PagoPay and ALT5 Sigma to launch a co-branded TON Mastercard for crypto-to-fiat spending [11] - AlphaTON is collaborating with SingularityNET and others to develop decentralized AI infrastructure within the Telegram ecosystem [11] Leadership and Governance - The company has strengthened its leadership team with key appointments, including a new CFO, CPO, CTO, and CMO, to support its growth strategy [13][16] - The leadership team brings extensive experience in blockchain economics, commercial strategy, technical infrastructure, and digital asset communications [16]

Core Insights - ECD Automotive Design, Inc. reported its third quarter financial results for 2025, highlighting a focus on operational improvements and cost containment while expanding its product lineup with new collaborations and builds [1][5][10]. Financial Performance - Revenue for the third quarter of 2025 was $5.8 million, a decrease from $6.4 million in the same quarter of 2024 [10][11]. - The company experienced a gross loss of $1.7 million in Q3 2025, compared to a gross profit of $2.0 million in Q3 2024, primarily due to the completion of legacy builds and increased tariff-related costs [10][11]. - Net income for the third quarter was $2.2 million, a significant improvement from a net loss of $2.6 million in the prior year, attributed to a non-cash gain from the conversion of debt into preferred stock [10][13]. - Operating expenses increased to $3.4 million, up by $0.8 million from the previous year, mainly due to higher legal fees and lease recognition [12]. - The operating loss for the quarter was reported at $5.0 million, an increase of $4.4 million from the prior year, driven by reduced gross margins and higher administrative costs [12]. Strategic Developments - The company is implementing cost-containment measures expected to yield over $1 million in annual savings through headcount and overhead reductions while maintaining craftsmanship and production capabilities [6][8]. - ECD has diversified its product offerings, including a collaboration with Chelsea Truck Company to produce modern Land Rover Defenders and INEOS Grenadiers, which is anticipated to enhance manufacturing resource utilization [7][10]. - The completion of the first bespoke Porsche 911 build marks ECD's entry into the Porsche restoration market, receiving recognition at a car show [7][10]. Future Outlook - Management believes that the operational groundwork established in Q3 2025 will lead to improved financial performance and sustained value creation as the company progresses into 2026 [8].

Core Insights - Mesoblast Limited is collaborating with the NIH-funded Blood and Marrow Transplant Clinical Trials Network to conduct a pivotal trial of Ryoncil for adults with severe steroid-refractory acute graft versus host disease (SR-aGvHD) [1][2][3] - The trial aims to address the high mortality rates in patients who do not respond to corticosteroids, with survival rates as low as 20-30% by Day 100 after failing ruxolitinib [2] - Ryoncil has shown promising results in pediatric patients, with a 76% survival rate at Day 100 in adults who failed other treatments [2][5] Company Overview - Mesoblast is a leader in developing allogeneic cellular medicines for severe inflammatory diseases, utilizing a proprietary mesenchymal lineage cell therapy technology platform [4][6] - The company has a strong intellectual property portfolio with over 1,000 patents or applications, providing commercial protection until at least 2044 [7] - Mesoblast is expanding its product offerings, with Ryoncil being developed for additional indications beyond SR-aGvHD, including biologic-resistant inflammatory bowel disease and heart failure [6] Clinical Development - The pivotal trial for Ryoncil will randomize patients as early as possible after corticosteroid refractoriness, comparing ruxolitinib alone versus ruxolitinib combined with Ryoncil [3] - The trial protocol is set to be submitted to the FDA to initiate enrollment in the first quarter of 2026 [3] - The collaboration with BMT CTN is significant as it represents U.S. centers performing approximately 80% of all U.S. allogeneic bone marrow transplants [1][10]

This represents an important step in advancing the “FFAI + AIXC” dual-flywheel, dual-bridge, and dual-listed company framework and supports the ongoing development of EAI + Crypto initiatives aimed at bridging Web2 and Web3.FFAI will continue advancing its EAI ecosystem while progressing toward key product milestones, including the first FX Super One pre-production vehicle coming off the U.S. line by year-end and the first delivery in the UAE on November 27.AIxC could benefit FFAI across five key areas: fin ...

MISSISSAUGA, Ontario, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended September 30, 2025. Key highlights include: (CAD)Q3 2025% Change vs.Q3 2024YTD 2025% Change vs.YTD 2024Trailing Twelve Months (TTM) Sept 30, 2025% Change vs.TTM Sept 30, 2024Canadian Pharma Sales9,864,254+19%28,351,130+16%<td style="border-right: solid black 1pt ; text-align: right ; vertical-align: middle; vertical-ali ...

Core Points - Namib Minerals will host a webcast and conference call for a business update on November 24, 2025, at 8:00 AM ET [1] - The company operates in the African gold mining sector, with a focus on Zimbabwe and the Democratic Republic of Congo [4] Company Information - Namib Minerals is a gold producer, developer, and explorer, significantly contributing to Africa's mining industry [4] - The company currently operates the How Mine, an underground gold mine in Zimbabwe, and plans to restart two additional assets in Zimbabwe [4] - Namib Minerals also has exploration assets in the Democratic Republic of Congo [4] Investor Engagement - Interested parties can access the live conference call via the company's Investor Relations website, and an archived replay will be available after the event [2] - Shareholders can submit questions for the management during the webcast by emailing the investor relations team [3]

Core Points - BioSyent Inc. has declared a quarterly dividend of $0.05 per common share, payable on December 15, 2025, to shareholders of record on November 28, 2025 [1] - The dividend for the fourth quarter of 2025 is consistent with the third quarter of 2025, indicating stable dividend policy [1] - The dividend qualifies as an 'eligible dividend' for Canadian income tax purposes [1] Company Overview - BioSyent Inc. is a profitable growth-oriented specialty pharmaceutical company listed on the TSX Venture Exchange under the symbol "RX" [2] - The company focuses on in-licensing or acquiring innovative pharmaceutical and healthcare products that are safe, effective, and have a proven track record [2] - BioSyent markets its products through community, specialty, and international business units to support healthcare professionals [2] Share Information - As of the date of the press release, BioSyent has 11,262,282 common shares outstanding [3]

Core Insights - Domo has partnered with Formula 1 driver Alex Albon to demonstrate the impact of data on performance in racing and business [2][4][6] - The collaboration will run through the 2026 season and includes various initiatives aimed at enhancing fan engagement and showcasing data-driven decision-making [2][4][5] Company Overview - Domo is an AI and Data Products platform that enables businesses to leverage data and AI for value creation [7] - The platform supports users in preparing, visualizing, automating, and distributing data products, enhancing the overall data journey [7] Partnership Details - The partnership will feature exclusive content, interactive experiences, and VIP hospitality opportunities at select Formula 1 races [5][6] - Domo and Albon aim to highlight the intersection of human instinct and data-driven intelligence in achieving measurable results [3][4] Industry Context - The collaboration emphasizes the importance of data in modern racing, where every decision is informed by billions of data points, paralleling the best practices in business [4][6] - The initiative aims to redefine fan engagement in Formula 1 by turning insights into impactful experiences [7]